This discrepancy can be explained by the fact that the “pathologist-determined tumor” contains regions of non-EGFR–expressing tissue, and PAI is designed to enhance contrast as a function of targeted molecule (in this case, EGFR expression). The gene discussed is EGFR; the disease is neoplasm.